Lv1
84 积分 2023-12-27 加入
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
1天前
待确认
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
13天前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
18天前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
25天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
The changing therapeutic landscape of small-cell lung cancer
1个月前
已完结
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer
2个月前
已关闭
The next generation of antibody–drug conjugates
2个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
2个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
2个月前
已完结
皖公网安备34019202002308
